PULMICORT RESPULES (budesonide) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. First approved in 2000.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
Pulmicort Respules is an inhaled corticosteroid suspension containing budesonide, a corticosteroid hormone receptor agonist used to treat inflammatory airway conditions. It works by binding to glucocorticoid receptors to reduce airway inflammation and improve breathing. The product is delivered via nebulizer for patients requiring inhaled corticosteroid therapy.
Product nearing loss of exclusivity with moderate competitive pressure (30/100), suggesting team focus shifting toward lifecycle management and cost-containment strategies rather than growth initiatives.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
Worked on PULMICORT RESPULES at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Pulmicort Respules offers exposure to lifecycle management and commercial strategy in a mature respiratory asset approaching patent expiration. Career value lies in managing competitive dynamics, optimizing market access, and executing LOE mitigation strategies within AstraZeneca's established franchise.